Novo Nordisk A/S (NVO)
| Market Cap | 212.92B -41.2% |
| Revenue (ttm) | 50.57B +8.1% |
| Net Income | 18.81B +16.6% |
| EPS | 4.23 +16.8% |
| Shares Out | 4.44B |
| PE Ratio | 11.32 |
| Forward PE | 15.86 |
| Dividend | $1.29 (2.68%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 7,079,720 |
| Open | 48.51 |
| Previous Close | 48.34 |
| Day's Range | 47.87 - 48.62 |
| 52-Week Range | 35.12 - 71.80 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 47.44 (-1.04%) |
| Earnings Date | Aug 5, 2026 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $47.44, which is a decrease of -1.04% from the latest price.
News
Medicare Expands Coverage for GLP-1 Weight Loss Drugs Boosting Novo Nordisk (NVO)
Medicare Expands Coverage for GLP-1 Weight Loss Drugs Boosting Novo Nordisk (NVO)
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new...
Novo Nordisk: A Buy After The 340B Reset, With The Pill As Optionality
Novo Nordisk: A Buy After The 340B Reset, With The Pill As Optionality
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50. But many seniors may be unaware o...
Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?
Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative. Novo's steady insulin cash flows and new MASH bet could expand growth beyond its core diabe...
Swiss pharma at risk of US trade investigation, industry body says
The United States could open a trade investigation into Switzerland's pharmaceutical industry similar to the one initiated last week against Germany, the head of Swiss industry body Interpharma said...
GLP-1s linked to smell and taste impairment in diabetes patients
We also report on a potentially simple solution to nausea experienced by cancer patients receiving morphine for pain.
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage
Novo Nordisk, the maker of Wegovy, introduced its GLP-1 pill for weight loss in early January, while Eli Lilly's pill, Foundayo, began shipping in April. In 2025, nearly half of all large employers co...
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees.
"The field is getting more crowded -- but Lilly is widening its lead,” said RBC analyst Trung Huynh. Until Novo Nordisk gets back to positive growth, and/or Eli Lilly's growth starts to slow down shar...
Novo Nordisk (NVO) Has an Obesity-and-Diabetes Platform Bigger Than a One-Drug Hype Cycle
Novo Nordisk (NYSE: NVO) is often discussed as if the whole equity story begins and ends with Ozempic or Wegovy.... The post Novo Nordisk (NVO) Has an Obesity-and-Diabetes Platform Bigger Than a One-D...
Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing
Lexaria Bioscience (LEXX) announces that dosing began on schedule on June 14th with Human Pilot Study #7, GLP-1-H26-7, that is evaluating two oral DehydraTECH-semaglutide compositions against Novo Nor...
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in cos...
Novo's top US exec wants more insurance coverage for weight-loss drugs
Denmark's Novo Nordisk , the maker of weight-loss drug Wegovy, hopes insurance will cover more U.S. users of the medication and balance direct-to-consumer sales that have driven the fast-growing mark...
From Injection to Pill
Dear reader, over the past few years, obesity treatment has become closely tied to injections. Drugs such as Ozempic, Wegovy (Novo Nordisk), and Zepbound (Eli Lilly) reshaped obesi...
Top Research Reports for Shell, Novo Nordisk & SAP
Shell, Novo Nordisk and SAP headline Zacks' top research reports, highlighting growth drivers, guidance outlooks and key risks shaping performance.
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
Eli Lilly's orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, an executive at the U.S. drugmaker told Reuters, as rival Novo Nordisk seeks to catch up in ...
Novo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued -- GF Score: 76/100
Novo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued -- GF Score: 76/100
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market. It's unclear how its candidate compares to competing programs that are still in clinica...
A Look at Novo Nordisk AS (NVO) After 6.2% Gain -- GF Value $144.58 vs Price $45.88
A Look at Novo Nordisk AS (NVO) After 6.2% Gain -- GF Value $144.58 vs Price $45.88
South Africa court bars iDexis from selling compounded Ozempic in Novo Nordisk case
South Africa's High Court has granted Novo Nordisk an interim interdict barring a local pharmacy group from manufacturing and selling compounded weight-loss medicines containing semaglutide, in a ...
Doctors say that GLP-1 medications can prevent lifelong obesity and Type 2 diabetes in children—but there are some worries
Doctors are looking for better options given the growing awareness of the serious health risks tied to childhood obesity.
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?
Novo Nordisk was the first to market with a GLP-1 weight-loss drug. It lost its early lead to Eli Lilly, which is now the name to beat in the GLP-1 race.
Novo Nordisk Stock Climbs as Analyst Flags Potential for More Wegovy Pill Sales
Novo Nordisk’s ($NVO) shares in Copenhagen closed roughly 5% higher on Friday. This came after Nordea ($NRDBY) went bullish on the Danish drugmaker, upgrading its NVO rating from Hold to…
Novo Nordisk Stock Rally as Owner Unveils $69 Million Obesity Research Push
Novo Nordisk Stock Rally as Owner Unveils $69 Million Obesity Research Push
Sumitomo Pharma, Novo Nordisk Win Japan Nod For Wegovy In MASH
(RTTNews) - Sumitomo Pharma Co., Ltd. (4506.T) announced on Friday that Japan has cleared Wegovy Subcutaneous Injection, which it co-promotes with Novo Nordisk B A/S (NVO), to treat metabolic dysfunct...